The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Variation in the miRNA-433 Binding Site of FGF20 Confers Risk for Parkinson Disease by Overexpression of α-Synuclein
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Specificity of microRNA target selection in translational repression
Doench, J. G., & Sharp, P. A. (2004) · Genes & Development · doi:10.1101/gad.1184404 · Cited by 1,636
MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135718 · Cited by 1,280
Clop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
Evolution of the Fgf and Fgfr gene families
Itoh, N., & Ornitz, D. M. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.08.007 · Cited by 1,096
Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease
Ibáñez, P., Bonnet, A.-M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., & Pollak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17104-3 · Cited by 1,044
Cited by
Non-coding RNAs in human disease
Esteller, M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3074 · Cited by 4,825
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
“, in which they have been shown to increase FGF20 translation in vivo , leading to increased expression of α-synuclein, one of the causative agents of this diseas”
miR2Disease: a manually curated database for microRNA deregulation in human disease
Jiang, Q., Wang, Y., Hao, Y., Juan, L., Teng, M., Zhang, X., Li, M., Wang, G., & Liu, Y. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn714 · Cited by 1,422
Self-citationBennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
MicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
Hsu, S.-D., Tseng, Y.-T., Shrestha, S., Lin, Y.-L., Khaleel, A., Chou, C.-H., Chu, C.-F., Huang, H.-Y., Lin, C.-M., Ho, S.-Y., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1266 · Cited by 1,041
miR-155 gene: A typical multifunctional microRNA
Faraoni, I., Antonetti, F. R., Cardone, J., & Bonmassar, E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.013 · Cited by 815
Repression of α-synuclein expression and toxicity by microRNA-7
Junn, E., Lee, K.-W., Jeong, B. S., Chan, T. W., Im, J.-Y., & Mouradian, M. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906277106 · Cited by 655
“Interestingly, a polymorphic variation in the miR-433 binding site of the fibroblast growth factor 20 (FGF20) gene was recently reported to confer risk of PD, which was attributed to increased FGF20 levels and indirectly enhanced -Syn expression (42).”
BackgroundFGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease
Qureshi, I. A., & Mehler, M. F. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3234 · Cited by 562
The role of microRNAs in human diseases
Tüfekci, K. U., Öner, M. G., Meuwissen, R. L. J., & Genç, Ş. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-748-8_3 · Cited by 566
Miñones-Moyano, E., Porta, S., Escaramís, G., Rabionet, R., Iraola, S., Kagerbauer, B., Espinosa-Parrilla, Y., Ferrer, I., Estivill, X., & Martí, E. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr210 · Cited by 482
Alterations of the microRNA network cause neurodegenerative disease
Hébert, S. S., & De Strooper, B. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.003 · Cited by 452
MicroRNA delivery through nanoparticles
Lee, S. W. L., Paoletti, C., Campisi, M., Osaki, T., Adriani, G., Kamm, R. D., Mattu, C., & Chiono, V. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.007 · Cited by 437
MicroRNA regulation of Alzheimer's Amyloid precursor protein expression
Hébert, S. S., Horré, K., Nicolaï, L., Bergmans, B., Papadopoulou, A. S., Delacourte, A., & De Strooper, B. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.11.009 · Cited by 436
Interactions of formulation excipients with proteins in solution and in the dried state
Ohtake, S., Kita, Y., & Arakawa, T. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.011 · Cited by 398
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., Shill, H., Adler, C., Sabbagh, M., Villa, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094839 · Cited by 385
Gong, J., Tong, Y., Zhang, H.-M., Wang, K., Hu, T., Shan, G., Sun, J., & Guo, A.-Y. (2012) · Human Mutation · doi:10.1002/humu.21641 · Cited by 372
Bhattacharya, A., Ziebarth, J. D., & Cui, Y. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1028 · Cited by 347
MicroRNA target site polymorphisms and human disease
Sethupathy, P., & Collins, F. S. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.07.004 · Cited by 333
Smalheiser, N. R., Lugli, G., Rizavi, H. S., Torvik, V. I., Turecki, G., & Dwivedi, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033201 · Cited by 324
A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease
International Parkinson's Disease Genomics Consortium (IPDGC), & Wellcome Trust Case Control Consortium 2 (WTCCC2) (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002142 · Cited by 314
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Epigenetic principles and mechanisms underlying nervous system functions in health and disease
MEHLER, M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.10.001 · Cited by 291
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
microRNAs miR-124, let-7d and miR-181a regulate Cocaine-induced Plasticity
Chandrasekar, V., & Dreyer, J.-L. (2009) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.08.009 · Cited by 279
Martí, E., Pantano, L., Bañez-Coronel, M., Llorens, F., Miñones-Moyano, E., Porta, S., Sumoy, L., Ferrer, I., & Estivill, X. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq575 · Cited by 276
Mellios, N., Huang, H.-S., Grigorenko, A., Rogaev, E., & Akbarian, S. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn201 · Cited by 274
Identification of blood microRNAs associated to Parkinsońs disease
Margis, R., Margis, R., & Rieder, C. R. M. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.01.023 · Cited by 263
Mishra, P. J., & Bertino, J. R. (2009) · Pharmacogenomics · doi:10.2217/14622416.10.3.399 · Cited by 260
Tabarés-Seisdedos, R., & Rubenstein, J. L. R. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.2 · Cited by 244
Understanding microRNAs in neurodegeneration
Eacker, S. M., Dawson, T. M., & Dawson, V. L. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2726 · Cited by 239
MicroRNAs: biomarkers, diagnostics, and therapeutics
Huang, W. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7046-9_4 · Cited by 237
An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model
Selvamani, A., Sathyan, P., Miranda, R. C., & Sohrabji, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032662 · Cited by 217
“In conclusion, a rapidly growing body of literature on miRNA’s role in cancer [66], neurodegenerative diseases [67–72] and MicroRNA Therapy for Stroke”
BackgroundNeuronal dark matter: the emerging role of microRNAs in neurodegeneration
Goodall, E. F., Heath, P. R., Bandmann, O., Kirby, J., & Shaw, P. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00178 · Cited by 187
MicroRNAs in neurodegenerative diseases and their therapeutic potential
Junn, E., & Mouradian, M. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.10.002 · Cited by 186
Noncoding RNAs in neurodegeneration
Salta, E., & De Strooper, B. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.90 · Cited by 183
Briggs, C. E., Wang, Y., Kong, B., Woo, T.-U. W., Iyer, L. K., & Sonntag, K. C. (2015) · Brain Research · doi:10.1016/j.brainres.2015.05.021 · Cited by 113
““PDspecific” miRNA/target associations of interest have been miR-7, miR-153, and miR-34b/c with α-Synuclein, (Doxakis, 2010; Junn et al., 2009; Kabaria et al., 2015), miR-433 with FGF20 (Wang et al., 2008), miR-133b with PITX3 (Kim et al., 2007), let-7a-5p, miR-184-5p, and miR-205 with LRRK2 (Cho et al., 2013; Gehrke…”
microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases
Basak, I., Patil, K. S., Alves, G., Larsen, J. P., & Møller, S. G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2093-x · Cited by 107
Identification of aberrant circulating mi RNA s in Parkinson's disease plasma samples
Chen, L., Yang, J., Lü, J., Cao, S., Zhao, Q., & Yu, Z. (2018) · Brain and Behavior · doi:10.1002/brb3.941 · Cited by 96
“…al., 2010; Cardo et al., 2013; Filatova et al., 2012; Junn et al., 2009; Khoo et al., 2012; Mouradian, 2012; Salta & De Strooper, 2012; Serafin et al., 2014; Shioya et al., 2010; Wang et al., 2008), two reference small RNAs and one NTC (no template control) were customized and prepared by miRGenes.”
MethodMiRNA Profile in the Substantia Nigra of Parkinson’s Disease and Healthy Subjects
Cardo, L. F., Coto, E., Ribacoba, R., Menéndez, M., Moris, G., Suárez, E., & Alvarez, V. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0428-y · Cited by 75
Yang, Z., Li, T., Li, S., Wei, M., Qi, H., Shen, B., Chang, R. C.-C., Le, W., & Piao, F. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00460 · Cited by 67
Yang, C. P., Zhang, Z. H., Zhang, L. H., & Rui, H. C. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0828-2 · Cited by 51
Matuszek, G., & Talebizadeh, Z. (2009) · BMC Medical Genetics · doi:10.1186/1471-2350-10-102 · Cited by 48
MicroRNAs: Possible role in pathogenesis of Parkinson’s disease
Filatova, E. V., Alieva, A. K., Shadrina, M. I., & Slominsky, P. A. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912080020 · Cited by 39
MicroRNAs targeting Nicastrin regulate Aβ production and are affected by target site polymorphisms
Delay, C., Dorval, V., Fok, A., Grenier-Boley, B., Lambert, J.-C., Hsiung, G.-Y., & Hébert, S. S. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00067 · Cited by 28
“For instance, the Parkinson’s disease-associated rs12720208 SNP is located in the miR-433 target site of Fibroblast growth factor 20, and affects miRNA-mediated repression (Wang et al., 2008).”
BackgroundInfluentialDifferentially Expressed miRNAs in Age-Related Neurodegenerative Diseases: A Meta-Analysis
Noronha, O., Mesarosovo, L., Anink, J. J., Iyer, A., Aronica, E., & Mills, J. D. (2022) · Genes · doi:10.3390/genes13061034 · Cited by 21
miRNA mutations are not a common cause of deafness
Hildebrand, M. S., Witmer, P. D., Xu, S., Newton, S. S., Kahrizi, K., Najmabadi, H., Valle, D., & Smith, R. J. H. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33299 · Cited by 14
Metadata
- Authors
- Wang, G., van der Walt, J. M., Mayhew, G., Li, Y.-J., Züchner, S., Scott, W. K., Martin, E. R., & Vance, J. M.
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 82
- Issue
- 2
- Pages
- 283-289
- ISSN
- 0002-9297 (ISSN-L)
- OpenAlex
- W1981506621
- Cited by
- 440
- References
- 33
- FWCI
- 27.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.